Launch Libervant buccal film

Deadline not yet reached (430 days left)

What the company said

“Potential annual revenue after anticipated launch in 2027.”

SourceAquestive Therapeutics, Inc. Form 8-K press release, 2026-09-25
Archived copyWayback Machine snapshot
FilingSEC filing index
Deadline as statedin 2027
Deadline used31 Dec 2027, the last day of the stated period
TypeProduct
Permanent referenceKI-C-2026-AQST-000852
Cite as https://keptindex.org/c/KI-C-2026-AQST-000852/ — this address never changes.

The deadline has not passed yet, so there is nothing to check. We look for evidence starting 30 days after 31 Dec 2027.

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Version 1 · original · stated 25 Sep 2026

Deadline 31 Dec 2027 (“in 2027”) · wording expected
Version 2 · stated 14 Oct 2026

Deadline 30 Apr 2027 (“April 2027”) · wording expected

“we are excited to work with Aquestive toward an anticipated April 2027 launch”
Source for this version

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Commercial launch
Indicative materiality: Medium rules
Action: Launch
Deliverable: Libervant buccal film
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium
Conditional: Yes: upon expiration of the orphan drug market exclusivity of an approved FDA product of another company
Depends on: Regulatory

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Aquestive Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.